Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer

The use of conventional methods for the treatment of cancer, such as chemotherapy or radiotherapy, and approaches such as brachytherapy in conjunction with the unique properties of nanoparticles could enable the development of novel theranostic agents. The aim of our current study was to evaluate th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecules (Basel, Switzerland) Switzerland), 2024-02, Vol.29 (5)
Hauptverfasser: Salvanou, Evangelia-Alexandra, Kolokithas-Ntoukas, Argiris, Prokopiou, Danai, Theodosiou, Maria, Efthimiadou, Eleni, Koźmiński, Przemysław, Xanthopoulos, Stavros, Avgoustakis, Konstantinos, Bouziotis, Penelope
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 5
container_start_page
container_title Molecules (Basel, Switzerland)
container_volume 29
creator Salvanou, Evangelia-Alexandra
Kolokithas-Ntoukas, Argiris
Prokopiou, Danai
Theodosiou, Maria
Efthimiadou, Eleni
Koźmiński, Przemysław
Xanthopoulos, Stavros
Avgoustakis, Konstantinos
Bouziotis, Penelope
description The use of conventional methods for the treatment of cancer, such as chemotherapy or radiotherapy, and approaches such as brachytherapy in conjunction with the unique properties of nanoparticles could enable the development of novel theranostic agents. The aim of our current study was to evaluate the potential of iron oxide nanoparticles, coated with alginic acid and polyethylene glycol, functionalized with the chemotherapeutic agent doxorubicin and the monoclonal antibody bevacizumab, to serve as a nanoradiopharmaceutical agent against breast cancer. Direct radiolabeling with the therapeutic isotope Lutetium-177 ([sup.177]Lu) resulted in an additional therapeutic effect. Functionalization was accomplished at high percentages and radiolabeling was robust. The high cytotoxic effect of our radiolabeled and non-radiolabeled nanostructures was proven in vitro against five different breast cancer cell lines. The ex vivo biodistribution in tumor-bearing mice was investigated with three different ways of administration. The intratumoral administration of our functionalized radionanoconjugates showed high tumor accumulation and retention at the tumor site. Finally, our therapeutic efficacy study performed over a 50-day period against an aggressive triple-negative breast cancer cell line (4T1) demonstrated enhanced tumor growth retention, thus identifying the developed nanoparticles as a promising nanobrachytherapy agent against breast cancer.
doi_str_mv 10.3390/molecules29051030
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A786438142</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A786438142</galeid><sourcerecordid>A786438142</sourcerecordid><originalsourceid>FETCH-LOGICAL-g137t-d00f47eb80771790a17af50946b5144ab9e632122eb16592180df15e762fffa3</originalsourceid><addsrcrecordid>eNptkD1PwzAQhiMEEqXwA9gsMaf4K19jWyhUqujSvTo759QocarEgbY7_xsLGDqgG97T6blHp4uie0YnQhT0sWlr1EONPS9owqigF9GISU5jQWVxedZfRzd9_04pZ5Ilo-hrNcQrUFhjSZZd68j6YEskb-DaPXTe6qAki8Fpb1sHtT0F7tP6HXlqD203KKutI-BKMsMP0PY0NKAI9D8C1YHeHf0OO9gfybRC53sCFVjXezLrEELMwWnsbqMrA3WPd385jjaL5838NV6tX5bz6SqumMh8XFJqZIYqp1nGsoICy8AktJCpSpiUoApMBWeco2JpUnCW09KwBLOUG2NAjKOHX20FNW6tM60PJza219tplqdS5OFNgZr8Q4UqsbG6dWhsmJ8tfANYpnWO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer</title><source>DOAJ Directory of Open Access Journals</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Salvanou, Evangelia-Alexandra ; Kolokithas-Ntoukas, Argiris ; Prokopiou, Danai ; Theodosiou, Maria ; Efthimiadou, Eleni ; Koźmiński, Przemysław ; Xanthopoulos, Stavros ; Avgoustakis, Konstantinos ; Bouziotis, Penelope</creator><creatorcontrib>Salvanou, Evangelia-Alexandra ; Kolokithas-Ntoukas, Argiris ; Prokopiou, Danai ; Theodosiou, Maria ; Efthimiadou, Eleni ; Koźmiński, Przemysław ; Xanthopoulos, Stavros ; Avgoustakis, Konstantinos ; Bouziotis, Penelope</creatorcontrib><description>The use of conventional methods for the treatment of cancer, such as chemotherapy or radiotherapy, and approaches such as brachytherapy in conjunction with the unique properties of nanoparticles could enable the development of novel theranostic agents. The aim of our current study was to evaluate the potential of iron oxide nanoparticles, coated with alginic acid and polyethylene glycol, functionalized with the chemotherapeutic agent doxorubicin and the monoclonal antibody bevacizumab, to serve as a nanoradiopharmaceutical agent against breast cancer. Direct radiolabeling with the therapeutic isotope Lutetium-177 ([sup.177]Lu) resulted in an additional therapeutic effect. Functionalization was accomplished at high percentages and radiolabeling was robust. The high cytotoxic effect of our radiolabeled and non-radiolabeled nanostructures was proven in vitro against five different breast cancer cell lines. The ex vivo biodistribution in tumor-bearing mice was investigated with three different ways of administration. The intratumoral administration of our functionalized radionanoconjugates showed high tumor accumulation and retention at the tumor site. Finally, our therapeutic efficacy study performed over a 50-day period against an aggressive triple-negative breast cancer cell line (4T1) demonstrated enhanced tumor growth retention, thus identifying the developed nanoparticles as a promising nanobrachytherapy agent against breast cancer.</description><identifier>ISSN: 1420-3049</identifier><identifier>EISSN: 1420-3049</identifier><identifier>DOI: 10.3390/molecules29051030</identifier><language>eng</language><publisher>MDPI AG</publisher><subject>Breast cancer ; Ferric oxide ; Health aspects ; Iron compounds ; Nanoparticles</subject><ispartof>Molecules (Basel, Switzerland), 2024-02, Vol.29 (5)</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Salvanou, Evangelia-Alexandra</creatorcontrib><creatorcontrib>Kolokithas-Ntoukas, Argiris</creatorcontrib><creatorcontrib>Prokopiou, Danai</creatorcontrib><creatorcontrib>Theodosiou, Maria</creatorcontrib><creatorcontrib>Efthimiadou, Eleni</creatorcontrib><creatorcontrib>Koźmiński, Przemysław</creatorcontrib><creatorcontrib>Xanthopoulos, Stavros</creatorcontrib><creatorcontrib>Avgoustakis, Konstantinos</creatorcontrib><creatorcontrib>Bouziotis, Penelope</creatorcontrib><title>Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer</title><title>Molecules (Basel, Switzerland)</title><description>The use of conventional methods for the treatment of cancer, such as chemotherapy or radiotherapy, and approaches such as brachytherapy in conjunction with the unique properties of nanoparticles could enable the development of novel theranostic agents. The aim of our current study was to evaluate the potential of iron oxide nanoparticles, coated with alginic acid and polyethylene glycol, functionalized with the chemotherapeutic agent doxorubicin and the monoclonal antibody bevacizumab, to serve as a nanoradiopharmaceutical agent against breast cancer. Direct radiolabeling with the therapeutic isotope Lutetium-177 ([sup.177]Lu) resulted in an additional therapeutic effect. Functionalization was accomplished at high percentages and radiolabeling was robust. The high cytotoxic effect of our radiolabeled and non-radiolabeled nanostructures was proven in vitro against five different breast cancer cell lines. The ex vivo biodistribution in tumor-bearing mice was investigated with three different ways of administration. The intratumoral administration of our functionalized radionanoconjugates showed high tumor accumulation and retention at the tumor site. Finally, our therapeutic efficacy study performed over a 50-day period against an aggressive triple-negative breast cancer cell line (4T1) demonstrated enhanced tumor growth retention, thus identifying the developed nanoparticles as a promising nanobrachytherapy agent against breast cancer.</description><subject>Breast cancer</subject><subject>Ferric oxide</subject><subject>Health aspects</subject><subject>Iron compounds</subject><subject>Nanoparticles</subject><issn>1420-3049</issn><issn>1420-3049</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptkD1PwzAQhiMEEqXwA9gsMaf4K19jWyhUqujSvTo759QocarEgbY7_xsLGDqgG97T6blHp4uie0YnQhT0sWlr1EONPS9owqigF9GISU5jQWVxedZfRzd9_04pZ5Ilo-hrNcQrUFhjSZZd68j6YEskb-DaPXTe6qAki8Fpb1sHtT0F7tP6HXlqD203KKutI-BKMsMP0PY0NKAI9D8C1YHeHf0OO9gfybRC53sCFVjXezLrEELMwWnsbqMrA3WPd385jjaL5838NV6tX5bz6SqumMh8XFJqZIYqp1nGsoICy8AktJCpSpiUoApMBWeco2JpUnCW09KwBLOUG2NAjKOHX20FNW6tM60PJza219tplqdS5OFNgZr8Q4UqsbG6dWhsmJ8tfANYpnWO</recordid><startdate>20240201</startdate><enddate>20240201</enddate><creator>Salvanou, Evangelia-Alexandra</creator><creator>Kolokithas-Ntoukas, Argiris</creator><creator>Prokopiou, Danai</creator><creator>Theodosiou, Maria</creator><creator>Efthimiadou, Eleni</creator><creator>Koźmiński, Przemysław</creator><creator>Xanthopoulos, Stavros</creator><creator>Avgoustakis, Konstantinos</creator><creator>Bouziotis, Penelope</creator><general>MDPI AG</general><scope/></search><sort><creationdate>20240201</creationdate><title>Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer</title><author>Salvanou, Evangelia-Alexandra ; Kolokithas-Ntoukas, Argiris ; Prokopiou, Danai ; Theodosiou, Maria ; Efthimiadou, Eleni ; Koźmiński, Przemysław ; Xanthopoulos, Stavros ; Avgoustakis, Konstantinos ; Bouziotis, Penelope</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g137t-d00f47eb80771790a17af50946b5144ab9e632122eb16592180df15e762fffa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Breast cancer</topic><topic>Ferric oxide</topic><topic>Health aspects</topic><topic>Iron compounds</topic><topic>Nanoparticles</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salvanou, Evangelia-Alexandra</creatorcontrib><creatorcontrib>Kolokithas-Ntoukas, Argiris</creatorcontrib><creatorcontrib>Prokopiou, Danai</creatorcontrib><creatorcontrib>Theodosiou, Maria</creatorcontrib><creatorcontrib>Efthimiadou, Eleni</creatorcontrib><creatorcontrib>Koźmiński, Przemysław</creatorcontrib><creatorcontrib>Xanthopoulos, Stavros</creatorcontrib><creatorcontrib>Avgoustakis, Konstantinos</creatorcontrib><creatorcontrib>Bouziotis, Penelope</creatorcontrib><jtitle>Molecules (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salvanou, Evangelia-Alexandra</au><au>Kolokithas-Ntoukas, Argiris</au><au>Prokopiou, Danai</au><au>Theodosiou, Maria</au><au>Efthimiadou, Eleni</au><au>Koźmiński, Przemysław</au><au>Xanthopoulos, Stavros</au><au>Avgoustakis, Konstantinos</au><au>Bouziotis, Penelope</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer</atitle><jtitle>Molecules (Basel, Switzerland)</jtitle><date>2024-02-01</date><risdate>2024</risdate><volume>29</volume><issue>5</issue><issn>1420-3049</issn><eissn>1420-3049</eissn><abstract>The use of conventional methods for the treatment of cancer, such as chemotherapy or radiotherapy, and approaches such as brachytherapy in conjunction with the unique properties of nanoparticles could enable the development of novel theranostic agents. The aim of our current study was to evaluate the potential of iron oxide nanoparticles, coated with alginic acid and polyethylene glycol, functionalized with the chemotherapeutic agent doxorubicin and the monoclonal antibody bevacizumab, to serve as a nanoradiopharmaceutical agent against breast cancer. Direct radiolabeling with the therapeutic isotope Lutetium-177 ([sup.177]Lu) resulted in an additional therapeutic effect. Functionalization was accomplished at high percentages and radiolabeling was robust. The high cytotoxic effect of our radiolabeled and non-radiolabeled nanostructures was proven in vitro against five different breast cancer cell lines. The ex vivo biodistribution in tumor-bearing mice was investigated with three different ways of administration. The intratumoral administration of our functionalized radionanoconjugates showed high tumor accumulation and retention at the tumor site. Finally, our therapeutic efficacy study performed over a 50-day period against an aggressive triple-negative breast cancer cell line (4T1) demonstrated enhanced tumor growth retention, thus identifying the developed nanoparticles as a promising nanobrachytherapy agent against breast cancer.</abstract><pub>MDPI AG</pub><doi>10.3390/molecules29051030</doi></addata></record>
fulltext fulltext
identifier ISSN: 1420-3049
ispartof Molecules (Basel, Switzerland), 2024-02, Vol.29 (5)
issn 1420-3049
1420-3049
language eng
recordid cdi_gale_infotracmisc_A786438142
source DOAJ Directory of Open Access Journals; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry
subjects Breast cancer
Ferric oxide
Health aspects
Iron compounds
Nanoparticles
title Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T18%3A29%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lu-Labeled%20Iron%20Oxide%20Nanoparticles%20Functionalized%20with%20Doxorubicin%20and%20Bevacizumab%20as%20Nanobrachytherapy%20Agents%20against%20Breast%20Cancer&rft.jtitle=Molecules%20(Basel,%20Switzerland)&rft.au=Salvanou,%20Evangelia-Alexandra&rft.date=2024-02-01&rft.volume=29&rft.issue=5&rft.issn=1420-3049&rft.eissn=1420-3049&rft_id=info:doi/10.3390/molecules29051030&rft_dat=%3Cgale%3EA786438142%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A786438142&rfr_iscdi=true